Eltrombopag NEW
| Price | $40 | $60 | $98 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-26 |
Product Details
| Product Name: Eltrombopag | CAS No.: 496775-61-2 |
| Purity: 99.73% | Supply Ability: 10g |
| Release date: 2026/05/26 |
Product Introduction
Bioactivity
| Name | Eltrombopag |
| Description | Eltrombopag (SB-497115-GR), an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110). |
| In vitro | Eltrombopag demonstrates a half maximal effective concentration (EC50) of 0.27 μM in murine BAF3 cells transfected with the luciferase reporter gene under direction of the STAT-activated IRF-1 promoter and human TpoR (BAF3/IRF-1/hTpoR). Eltrombopag activates the receptor by association with metal ions (i.e., Zn2+) and specific amino acids within the transmembrane and juxtamembrane domains of the TpoR. Eltrombopag (30 μM) results in activation of STAT5 in N2C-Tpo cells, as detected with an antiphospho-STAT5 antibody on Western blots. Eltrombopag stimulates proliferation after a 2-day incubation with an EC50 of 0.03 μM in a BrdU assay conducted in BAF3/hTpoR cells. Eltrombopag also induces differentiation of hematopoietic stem cells into committed megakaryocyte progenitor cells. Eltrombopag increases the differentiation of bone marrow CD34+ cells into CD41+ megakaryocytes in a dose-dependent manner with an EC50 of 0.1 μM. [1] Eltrombopag inhibits N2C-Tpo cell and HEL92.1.7 cell proliferating with IC50 of 20.7 μg/mL and 2.3 μg/mL.[2] Eltrombopag (20 μg/mL) leads to a decreased cell division rate, a block in G(1) phase of cell cycle, and increased differentiation in human and murine leukemia cells. Eltrombopag (5 μg/mL) shows clear signs of differentiation, significant changes in the organization of the nuclear contents, and an increase in the cytoplasm/nucleus ratio in HL60 cells. Eltrombopag (5 μg/mL) causes an increase in CD11b, which is consistent with a premacrophage state in U937 cells, and also causes an increase in CD11b in URE cells. Eltrombopag leads to a reduction in free intracellular iron in leukemic cells in a dose-dependent manner in HL60 cells. [3] |
| In vivo | Eltrombopag (10 mg/kg per day) increases platelet counts over twofold approximately 1 week after the last dose for one chimpanzee and approximately 1.5-fold for the other two chimpanzees. [1] Eltrombopag (1 mg/mL) prolongs survival in mouse models of leukemia. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.26 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 10 mg/mL (22.6 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | Thrombopoietin receptor | SB497115 | SB 497115 | N2C-Tpo | megakaryocyte | Inhibitor | inhibit | immune thrombocytopenia | hepatocellular carcinomab | hematopoiesis | Eltrombopag | chimpanzee | CD34 | blood platelet | BAF3 | Bacterial | Apoptosis |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Imidazole | Formamide | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library | Coagulation and Anticoagulation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $10.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-11-04 | ||
| $10.00 |
Hebei Zhuanglai Chemical Trading Co.,Ltd
|
2024-06-04 | ||
| $3.00 |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-22 | ||
| $65.00 |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2023-11-04 | |
|
VIP4Y
|
shandong perfect biotechnology co.ltd
|
2023-08-14 | ||
| $50.00 |
Henan Bao Enluo International TradeCo.，LTD
|
2023-08-01 | ||
|
VIP5Y
|
Sinoway Industrial co., ltd.
|
2023-02-07 | ||
|
VIP4Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-22 | ||
|
Zhejiang Hengkang Pharmaceutical Co., Ltd.
|
2022-09-02 | |||
|
Hangzhou Huarong Pharm Co., Ltd.
|
2021-09-18 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY